HOME >> BIOLOGY >> NEWS
Found: Key 'go-between' in heart disease

Medical researchers at the University of New South Wales (UNSW) have shed light on a little-known mechanism involved in the thickening of arteries, a process associated with heart disease.

"Essentially we've uncovered a complex network of how one bad guy regulates another bad guy," said Professor Levon Khachigian, of the Centre for Vascular Research (CVR) at UNSW. "We've also found a key to stopping this Mafioso network."

Arteries thicken when tiny molecules are increased in blood vessels. These are known as 'growth factors', which make the space in the arteries narrower and make it harder for blood to pass through.

The team's research focuses on one of four parts that make up a certain growth factor family known as PDGF. The work relates to the D chain of that growth factor.

"Our investigations have found that a key peptide hormone called angiotensin controls the expression of an important part of PDGF," said Professor Khachigian.

"Angiotensin has long been implicated in cardiovascular ailments like high blood pressure, restenosis and atherosclerosis", he said. "Angiotensin uses a couple of 'middle men' in the cell to jack up levels of PDGF D chain".

"These 'go betweens' are crucial to angiotensin's mode of action," he said. "If we take out these middle men (actually called transcription factors) we can greatly limit production of the growth factor, which is the result we would hope to see clinically."

"Our findings will provide future opportunities to tease out more specific inhibitors of growth factor production in order to reduce the incidence of common vascular disorders."

This is the first time PDGF D control has been studied at this molecular level.

The paper Inducible Platelet-Derived Growth Factor D-chain Expression by Angiotensin II and Hydrogen Peroxide Involves Transcriptional Regulation by Ets-1 and Sp1, has just been published in the influential international journal Blood.
'"/>

Contact: Susi Hamilton
susi.hamilton@unsw.edu.au
61-422-934-024
University of New South Wales
14-Mar-2006


Page: 1 2

Related biology news :

1. Found: Missing sequence of the human Y chromosome
2. High blood pressure, low energy -- a recipe for heart failure
3. Abnormal fat metabolism underlies heart problems in diabetic patients
4. Cardio exercise benefits in male vs. female hearts
5. Using stem cells to help heart attack victims
6. System to analyze beating heart stem cells could lead to heart attack treatments
7. Cardiac patches stimulate regeneration, improve function after heart attack
8. Specific type of cell death may accelerate decompensated heart failure
9. Faulty cell membrane repair causes heart disease
10. Link between obesity and enlarged heart discovered by University of Arizona researchers
11. Genetic defect links respiratory disease and congenital heart disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Found Key between heart disease

(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., a ... therapeutic antibodies, today announced the advancement of ... into IND-enabling studies. The Company,s anti-IL-36R therapeutic ... for generalized pustular psoriasis (GPP), an orphan ... need. ANB019 is wholly owned within AnaptysBio,s proprietary ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... LAUSANNE , Switzerland ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ ... prescription drugs that target unmet medical needs ... that preclinical data on the investigational compounds ... inhibitor) will be presented at the 2015 ...
Breaking Biology Technology:Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: